Everolimus for Advanced Pancreatic Neuroendocrine Tumors

C. Yao, James; H. Shah, Manisha; Ito, Tetsuhide; Lombard Bohas, C.; M. Wolin, Edward; Van Cutsem, Eric; J. Hobday, Timothy; Okusaka, Takuji; Capdevila, Jaume; G.E. de Vries, Elisabeth; Tomassetti, Paola; Pavel, Marianne; Hoosen, Sakina; Haas, T; Lincy, Jeremie; Lebwohl, David; Öberg, Kjell

doi:10.1056/nejmoa1009290

Public

Everolimus for Advanced Pancreatic Neuroendocrine Tumors

Published in New England Journal of Medicine • Feb 9, 2011

Authors:

James C. Yao

Manisha H. Shah

Tetsuhide Ito

Abstract

BACKGROUND: Everolimus, an oral inhibitor of mammalian target of rapamycin (mTOR), has shown antitumor activity in patients with advanced pancreatic neuroendocrine tumors, in two phase 2 studies. We evaluated the agent in a prospective, randomized, phase 3 study. METHODS: We randomly assigned 410 pa...

Subject

Everolimus

Medicine

Neuroendocrine tumors

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!